Recovering scientist turned early stage VC A biotech optimist fighting gravity

Launching Science2Startup: Connecting Academics With Venture
October 6, 2017

We’re excited to announce the launch of Science2Startup, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities. This event is in many ways a relaunch of the successful URES (University Research

Leave a comment

Nimbus Therapeutics Reaches Summit For Deal With Celgene
October 3, 2017

Today Nimbus and Celgene announced a significant partnership focused on autoimmune and inflammatory diseases. The alliance includes two pre-clinical autoimmune-focused programs in various stages of drug discovery. The most advanced program is a highly selective inhibitor of Tyk2, an immunokinase

Leave a comment

VC-Backed Biotech Financings: Boom Or Bubble?
October 2, 2017

Private biotech funding numbers are in for the third quarter and on an absolute capital basis they are huge: $3.6B flowed into private biotechs, the largest quarter of VC-funding into biopharma ever in the history of our industry, according to

Leave a comment

Building Community: One Stride At A Time
September 26, 2017

Building a shared sense of community helps create the relationships and interactions that bring people together and make teams and sector ecosystems successful. Community is a core part of building a distinctive culture. With a portfolio of related investments, industry


Venturing Boldly Into Neuroscience
September 21, 2017

Neuroscience has quietly become a hot space for startups. Across a range of neurologic conditions, contrarian investors have been fueling entrepreneurs to discover and develop novel therapeutic strategies. Earlier this week, two Atlas-founded companies, Rodin Therapeutics and Disarm Therapeutics, both announced

1 Comment

Alternative Perspectives On The Biotech M&A Environment
September 7, 2017

Last month, Bloomberg bemoaned the dearth of biotech M&A, and pundits echoed the sentiment (here, here), citing concerns about tax rates and drug pricing. The top line numbers in Bloomberg’s graph certainly paint a dim view of 2017’s global biotech

1 Comment

New Blood Needed: Pharma R&D Leadership Tenure
September 5, 2017

It’s all about people, it always is. Human capital is a company’s most important asset. Successful companies have human capital management strategies that excel at talent recruitment, and prioritize career development and retention. But human capital is never static, and

Leave a comment

Crossing The Sea: Adventures In Transatlantic Biotech Operations
August 24, 2017

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC. On my first morning as a US-based employee, I took advantage of the hotel’s shopping service by ordering the

Leave a comment

Innately Innovative: IFM Therapeutics Acquired By BMS
August 3, 2017

Today BMS announced the acquisition of IFM Therapeutics, an emerging biotech focused on modulating core innate immune pathways to treat cancer and autoimmune disease. As described in the press release, BMS will acquire the company for $300M upfront, with potentially

1 Comment

Distinctive Biotech Corporate Culture: Walk The Talk
July 25, 2017

Corporate culture is often hard to precisely define. Yet it’s always cited as being one of the key drivers of company outperformance, especially for startups. Recently I was asked to define what culture means by a young entrepreneur: beyond the


Atlas Cranks It Up To Eleven: Fund XI
June 29, 2017

Today we announced the closing of Atlas Venture Fund XI, a $350M investment vehicle focused exclusively on early stage biotech investing. Since launching our fundraising process in April, we’ve received a truly humbling level of support and interest in our

1 Comment

Hiring:  Using Your Team To Build A Team
June 16, 2017

This blog was written by Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC. Much has been said about who and when to hire in this blog (here and here for example), but

Leave a comment